VEDBAEK, Denmark, June 30 /PRNewswire-FirstCall/ -- Exiqon A/S today received information from Danske Bank, that the Danske Bank Group - including Danica Pension Livsforsikring and Danske Fund FCP - through acquisition today of 502,300 shares now owns 1,804,514 shares of a nominal value of each DKK 1 corresponding to 5,99% of the share capital and 5,99% of the voting rights in Exiqon A/S.
Exiqon's corporate mission is to combine leading-edge scientific
expertise in gene expression with our proprietary LNA(TM) technology.
Exiqon's products, services and scientific staff enable life science
researchers to make groundbreaking discoveries. Moreover, Exiqon is
addressing the unmet need for a new approach to the diagnosis of cancer.
Exiqon's products are based on patented technology (LNA(TM) or Locked
Nucleic Acids) that facilitates very precise and sensitive analysis of
nucleic acids. Exiqon aims to expand the existing product offering for
research use as well as to develop new proprietary molecular diagnostic
products. Exiqon, through a number of recent initiatives, has positioned
itself as a significant player in applying miRNA as the key biomarker in
cancer diagnostics. Exiqon has facilities in Denmark, Boston (MA) and
For more information, please contact:
Lars Kongsbak, President and CEO, tel. +45-40-90-21-01,
Hans Henrik Chrois Christensen, CFO, tel. +45-40-90-2131.
Copyright©2008 PR Newswire.
All rights reserved